Novo Nordisk Discloses Insider Trading Activity
Ticker: NONOF · Form: 6-K · Filed: Aug 19, 2025 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
Related Tickers: NVO
TL;DR
Novo Nordisk board/execs bought/sold shares on Aug 19, 2025. See 6-K.
AI Summary
On August 19, 2025, Novo Nordisk A/S filed a Form 6-K to report transactions in its shares by board members, executives, and associated persons. This disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Why It Matters
This filing provides transparency into the trading activities of key individuals within Novo Nordisk, which can offer insights into their confidence in the company's performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of insider trading activity, not a material event impacting the company's operations or financial health.
Key Players & Entities
- NOVO NORDISK A S (company) — Filer
- August 19, 2025 (date) — Filing date and transaction date
- Regulation No. 596/2014 (regulation) — Governing market abuse disclosures
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When were these transactions reported?
The transactions were reported on August 19, 2025.
What is the purpose of this filing?
The purpose of this Form 6-K is to report data of transactions made in Novo Nordisk shares by company insiders and their associated persons.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-08-19 08:35:12
Filing Documents
- f6k_081925.htm (6-K) — 29KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-005478.txt ( ) — 169KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: August 19, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer